Ipsen tries again in Parkinson’s disease with $363m IRLAB deal
pharmaphorum
JULY 16, 2021
French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden’s IRLAB for $28 million upfront. . It is due to readout in the first half of next year.
Let's personalize your content